Tag Archives: cannabis

Brayden Sutton on Getting “Back-to-Basics” in the Bud Business | The CSE Podcast Ep6-S3

The sixth episode of this year’s program has us catching up with Brayden Sutton, CEO of The BC Bud Corporation (CSE:BCBC).

Brayden isn’t just a CEO… he’s had a colorful career as a trader, as an entrepreneur, and investor at a young age. He’s even written a book called Money Mind: Beyond Speculation – a deep dive on his own journey in speculative investing and portfolio management. In this conversation we discuss what brought him back to the cannabis industry after his experiences with Supreme Cannabis and 1933 Industries and then we dive deeper into the motivations for writing a personal finance book.

About The BC Bud Corporation: The BC Bud Co is a house of brands created by industry professionals who are passionate about the user experience and ever-changing consumer demand. Founder-led and based in British Columbia; we take the heritage of BC Bud seriously.

Learn more about The BC Bud Co at https://www.thebcbc.com/

Subscribe: Apple Podcasts / Spotify / Stitcher / Google Podcasts / iHeart / RSS

Ilan Sobel on Executing the “Scale-Up” | The CSE Podcast Ep2-S3

We start our second show of the season by revisiting one of the most memorable interviews from last season with Ilan Sobel, CEO of BioHarvest Sciences (CSE:BHSC). On last year’s interview we learned about the driving mission of his company to build “human utility value”. We use that as a jumping-off point as we re-unite after a notable year for the company despite global and economic headwinds.

Ilan provides an update on BioHarvest’s two key product verticals in the  Polyphenol and Cannabis sectors, and how each are taking unique (and in some cases, similar) paths to market. Ilan also reflects on some of the choices the company has made with respect to developing its sales funnel and shares valuable lessons about acting as a “learning” organization and listening to your customers.

Mr. Sobel is Chief Executive officer of  BioHarvest Sciences Inc. (CSE:BHSC)  –  the developer and exclusive owner of the proprietary and patent-protected BioFarming technology. It is the first and only industrial-scale plant cell technology capable of producing the active plant ingredients without the necessity to grow the plant itself. The Company’s technology is non-GMO and has already been validated by VINIA®, the red grapes cells functional food/dietary supplement produced and sold by BioHarvest Sciences Inc. The Company plans to generate significant revenue within the global nutraceutical ingredients and dietary supplements market with VINIA® and other Super Fruit Nutraceutical products. Further, by adapting this technology to the Cannabis plant, and building adequate production capacity, BioHarvest Sciences Inc.’s objective is to become a leading supplier of Cannabis for both medicinal and legal recreational purposes.

Learn more about BioHarvest Sciences at https://bioharvest.com/

Subscribe: Apple Podcasts / Spotify / Stitcher / Google Podcasts / iHeart / RSS

Jeffrey Guillot from Millennial Strategies on Cannabis Advocacy | The CSE Podcast Ep31-S2

Episode 31 of The Exchange for Entrepreneurs Podcast is live! The CSE’s Barrington Miller chats with Millennial Strategies Partner Jeffrey Guillot about the company’s lobbying work, cannabis legalization in the US, and New York State’s positioning within the industry. The conversation also addresses CAURD licenses, the illicit versus legal markets, and cannabis oversupply.

Here’s an overview of what Barrington and Jeffrey discuss in this edition of The Exchange for Entrepreneurs Podcast:

00:00 – Introduction
00:24 – What is Millennial Strategies all about?
01:42 – What does a lobbyist do?
03:06 – Cannabis in New York State
08:01 – New York State’s potential
11:15 – What will happen to the legacy market?
15:36 – Is Federal legalization possible?
21:45 – What can be done about oversupply?
25:20 – Where can we learn more about Millennial Strategies?

Learn more about Millennial Strategies at https://millennialstrat.com/

Subscribe: Apple Podcasts / Spotify / Stitcher / Google Podcasts / iHeart / RSS

InnoCan Pharma: Combining Cannabinoids and Cutting-Edge Science to Deliver Drugs on Target

Smart drug delivery systems that deliver medications to specific sites in the human body are on the leading edge of science.

This type of biomedical engineering focuses on maximizing drug efficiency and minimizing possible side effects, while reducing the overall amount of medication used and frequency of treatment.

Cannabinoids play a crucial role in regulating the immune system and have been shown to suppress inflammation through multiple anti-inflammatory pathways. Their high safety profile makes them an appealing alternative to many traditional drugs, according to Iris Bincovich, Chief Executive Officer of InnoCan Pharma (CSE:INNO). 

InnoCan is working to harness the unique qualities of cannabinoids and combine them with the latest in drug delivery systems. The goal is to deliver cannabinoids such as CBD so that more of it becomes available for the body to benefit from than with current platforms.

Bincovich recently spoke with Canadian Securities Exchange Magazine about working with university researchers on the combination of cannabinoids and innovative delivery systems, as well as the direction in which the company’s technologies are heading.

InnoCan recently reported the results of preclinical trials on dogs, using injections for both pain relief from osteoarthritis and for the treatment of epilepsy. What did you learn from these trials?

We learned that we can bring a substantially better bioavailability of CBD to the bloodstream.

The low oral bioavailability of CBD in people, at 6.5% to 20% of administered dosage, is a result of first pass metabolism in the liver and considered to be variable and dependent on fasting and fed conditions.

Together with The Hebrew University of Jerusalem, we’re developing injectable liposomal CBD formulations (LPT) that have already shown higher bioavailability of CBD and prolonged release to the bloodstream.

In a recent study, we’ve learned that the LPT showed close to 100% bioavailability of CBD and prolonged release for at least four weeks after one LPT subcutaneous injection.

In this preclinical trial, a dog with drug-resistant epilepsy was treated with InnoCan Pharma’s LPT injections. The results demonstrated that the frequency and intensity of the dog’s epileptic seizures decreased significantly. Since the last LPT injection, the dog has not had a seizure for over 10 weeks.

In another preclinical trial, six dogs suffering from osteoarthritis and treated with oral analgesics, but still experiencing pain, were administered a single LPT subcutaneous injection in addition to their routine analgesics. CBD concentrations were observed for six weeks following the liposomal CBD injection in the dogs’ plasma. Owners reported that the dogs’ pain and wellbeing scores improved for several weeks after the injection. The results show that the LPT technology has the potential to provide additional analgesia in dogs suffering from pain.

You’re starting by treating dogs for these conditions, and eventually moving on to the human side?

We’re gathering data for this purpose. We chose a big animal model for developing a drug and a treatment model. And yes, the veterinary industry is a potential market whereas the regulatory barriers are marked for the human pharma side.

In both pathways, veterinary and human, we see a lot of potential for the LPT technology to improve patients’ quality of life.

CBD-loaded exosomes (CLX) may hold the potential to regenerate cells. Could this work for conditions associated with the central nervous system?

Exosomes are small particles created when stem cells are multiplied. Lately, they are considered a very promising delivery platform for different molecules. The exosomes can be used as a delivery vehicle that can deliver cannabinoids to diverse target sites in the body.

Various cannabinoids were shown to protect neuronal cell death following their exposure to various oxidative stress damages.

We’re collaborating with Ramot at Tel Aviv University to develop a revolutionary cannabinoid-loaded exosome technology that may hold the potential to provide a highly synergistic therapeutic effect. This effect utilizes the regenerative and anti-inflammatory properties of exosomes and cannabinoids to target various conditions associated with the central nervous system.

What’s next for InnoCan?

The LPT platform development is now in the stage of collecting more safety and efficacy information, with a view toward human clinical trials.

From Q4 2022 going into 2023, we will commence targeting pharma veterinary companies, especially in the companion animal arena for pain management and epilepsy drugs, to initiate negotiation of licensing agreements.

In the three years since we went public, we’ve done an early exercise of warrants. Nearly 90% of our investors chose to exercise the warrants for total proceeds of C$9.2 million. We’re collaborating with leading scientific institutes, focusing on the development of the LPT and CLX drug delivery systems, to achieve our goals of presenting the market with more efficient and accurate delivery systems of cannabinoids to the body.

This story was featured in Canadian Securities Exchange Magazine.

Learn more about InnoCan Pharma at innocanpharma.com.

Marimed: More US Growth in the Works for This Consistently Profitable Cannabis Company

Consumer demand for legal cannabis continues to grow in the US despite stalled legalization efforts at the federal level. Analytics company New Frontier Data, for example, projects US cannabis sales will hit US$57 billion annually by 2030, with that number possibly reaching $72 billion if 18 additional states permit adult recreational use.

MariMed (CSE:MRMD) has developed into a premier seed-to-consumer multi-state operator with expertise in cultivation, production and dispensary operations. The company has a track record of sustainable revenue growth along with one of the strongest EBITDA margins in the industry, projecting $135 million to $140 million in revenue for 2022, as well as $35 million to $40 million in adjusted EBITDA.

The Canadian Securities Exchange Magazine recently spoke with MariMed President Jon Levine, who discussed the company’s growth prospects, how it plans to increase shareholder value and the ways in which US federal legalization efforts influence MariMed’s business.

What distinguishes MariMed from other US multi-state operators?

MariMed is a company that prides itself on its history and a leadership team with a strong track record of winning licences. We built this company over several years – first as advisors helping businesses win their applications and building out their facilities, and now as acquirers working to consolidate those businesses under the MariMed footprint.

Today, we have a lot of team members and facilities with deep industry knowledge, including several members of our executive leadership team. Our CEO Bob Fireman, COO Tim Shaw and I have been working together in this industry for more than a decade.

Why did you choose the states in which you operate, and do you have plans to expand to other states?

In the beginning, MariMed submitted applications in multiple states that were available for licensing and focused on getting those states up and running. Now that MariMed has consolidated the businesses in Illinois, Massachusetts and Maryland, we are focused on expanding to the maximum allowable by law in each of those states.

In Massachusetts, for example, we plan to add two more adult-use dispensaries to our fully vertical, seed-to-sale operation there. In Illinois, we recently added a cultivation-and-processing licence that, once operational, will make us fully vertical in that high-growth state, and we also acquired a licence to build a fifth adult-use dispensary. Illinois allows operators to own and operate a maximum of 10 dispensaries, so we are also focused on adding an additional five to maximize our retail operations in that state.

Additionally, we’re looking for other markets we can expand into that have limited licences and are within the larger regions we presently operate in. We can go in and do the same build out where we go fully vertical as quickly as possible.

What are MariMed’s plans to enhance shareholder value?  

We have an exciting future ahead of us. As I mentioned, we’re building out Illinois, Massachusetts and Maryland with additional locations. We’ve also recently won licences in Ohio and Connecticut. 

We’re also going to continue to expand into additional states through either acquisitions or through the licensing process. Then we’ll build them to be as fully vertical as quickly as possible.

We’re also going to expand our branded products, including Betty’s Eddies, Kalm Fusion, Bubby’s Baked and Vibations: High + Energy, which have all been very successful in each of the states in which they are presently distributed. We’re going to make them bigger and stronger, as well as expand them into additional states over the next several years.

How do you intend to finance your growth plans?

We’re presently cash-flow positive and generating additional cash every month. So, we’ve been using cash flow from operations to expand at a slower rate. But with the current down market making equity issuance not the best option for shareholders, there are opportunities to borrow non-dilutive money at attractive rates given our financial strength and clean balance sheet.

What impact, if any, has the government’s inability to introduce federal cannabis legalization had on your business?

It’s a disappointment for MariMed because we would like to see some form of the SAFE Banking Act passed. That’s less important for our company, as our strong management team has learned how to operate within these tough confines of borrowing and banking abilities for over a decade. The SAFE Banking Act is really about helping smaller cannabis entrepreneurs that are more challenged in gaining fair and equitable access to capital.

We would love to see the SAFE Banking Act passed, and with the right amount of social equity reform included in it. But even with the continued delays at the federal level, MariMed can still operate efficiently and successfully. We’re going full steam ahead in building additional opportunities for our investors.

Finally, what do your shareholders have to look forward to in the next 12 months? 

Our investors should expect continued success and growth. Over the next 12 months, we will open additional retail and cultivation facilities, generating more revenue, and increasing the number of consumers that can access our great brands. We’ve been very successful over the last few years, and we’re going to continue that trend.

Our shareholders should expect MariMed to have a strong balance sheet with the ability to expand our cash flow and to borrow money at reasonable rates to accelerate the expansion of our business to get to the next level. We may be considered a small MSO, but we are going to become much bigger. 

In this market, we have a wonderful opportunity to continue to grow. I think our shareholders will benefit from patience and expect that we will continue to grow over the next several years.

This story was featured in Canadian Securities Exchange Magazine.

Learn more about MariMed at marimedinc.com

Cresco Labs: Top-Tier House of Brands Acquires a Major Retail Network and Sets its Sights on Becoming Number One

Cresco Labs (CSE:CL) Chief Executive Officer Charlie Bachtell believes that when it comes to cannabis, brands matter just as much as in any other industry. Branding Cresco’s retail stores Sunnyside, rather than simply using the parent company name, is but one example of this concept at work.

There are 51 Sunnyside stores across seven states, all brightly coloured and selling products in packaging that would be right at home on the shelves of Whole Foods or CVS.

Different Cresco Labs products have their own unique branding too, depending on their target audience. There’s the namesake Cresco, the flagship “excellent everyday cannabis,” packaged in sleek, matte-coloured containers.

Then there’s Mindy’s, a line of restaurant quality edibles made in collaboration with a James Beard award-winning chef. The packaging has a deep red colour and black cursive font – it looks indulgent. It’s a Cresco Labs product just the same, but it has a totally different identity.

Bachtell emphasizes the importance of a house of brands strategy rather than what he calls a “branded house” where everything is named for the company itself. Consumers are loyal to brands they trust, and you cultivate that trust by speaking to your target audience.

“One thing we realized very early is that the cannabis consumer is very wide and varied,” Bachtell says. “You’ve got your 21-year-old male college student, but you’ve also got your 63-year-old grandmother. They’re effectively walking to the same store to buy the same product, but they want it to look and feel very differently from each other.”

The dedication to brand differentiation is paying off. Cresco Labs had the top branded product portfolio in the second quarter, according to cannabis sector analytics firm BDSA, including the top portfolio of branded flower, the top portfolio of branded concentrates, the second-highest portfolio of branded vapes and a top five portfolio of branded edibles.

The company grew even stronger in March when it announced a definitive agreement to acquire what Bachtell refers to as “the largest engine of value creation in the industry,” New York-based Columbia Care. Once complete, the acquisition will bring 131 facilities (99 dispensaries and 32 cultivation and manufacturing locations) into the Cresco Labs family in one fell swoop. The transaction is expected to close around year-end.

Creating scale in the US cannabis industry is a challenge, in no small part because regulations vary from state to state. Most cannabis companies, Cresco Labs included, generate 75% of their revenue from their three biggest states, according to Bachtell.

But with Columbia Care under the umbrella, Bachtell expects to have eight states contributing at least US$100 million to the top line in 2023. That’s significant diversification.

“We are matching the most productive per-store retail operating model with one of the largest combined retail store platforms in the industry,” Bachtell explained on the company’s earnings call to review the second quarter. “We are creating an unmatched diversification and balance of revenue by geography and by channel.”

Speaking of geography, Cresco Labs is number one in market share in Illinois, Pennsylvania and Massachusetts. The goal is to be in the top three in every state where the company operates.

Bachtell is based in Illinois, where before he co-founded Cresco, he was general counsel for a mortgage company. He started that job in 2007, just in time for the housing market to be engulfed by the Great Recession.

The mortgage industry went from relatively unregulated to highly regulated overnight, Bachtell says, and those in the business had to figure out how to navigate rapidly shifting sands.

When a colleague suggested they get into the cannabis business in 2013, Illinois was just about to pass a law legalizing medical cannabis. Bachtell was skeptical it would be a good fit for him, but then he saw the legislation.

As it turned out, mortgage banking and cannabis sales have something in common.

“I read the bill, and it was as well-drafted and thorough as legislation that was geared toward that banking industry through the last five years of crazy regulatory and legislative initiatives,” he says. “I felt like I had read this book before.”

What Bachtell realized then is that cannabis would never be less regulated than it was at the time. Especially if federal legalization eventually became law, cannabis would develop into a consumer product whether the industry knew it then or not.

The cannabis industry, according to Cresco, can be broken down into four verticals: cultivation and manufacturing, building consumer brands, distributing those brands onto as many shelves as possible, and retail locations. The goal is to excel at all four, but Cresco is prioritizing the middle two. That’s the way the wind is blowing, according to Bachtell.

For example, if cannabis products do end up on the shelves of your local pharmacy, that makes brands more important than brick and mortar retail stores.

Illinois also became the first state to require that products be packaged in childproof containers. That cemented the importance of packaging in what Cresco Labs considers its mission to this day: normalizing, professionalizing and revolutionizing cannabis.

“If Illinois was going to require you to put it in a container, then that becomes your Coca-Cola can, your Budweiser bottle, your Marlboro cigarette pack, your Tylenol box,” Bachtell explains. “However you want to think about cannabis, it just became a consumer product good.”

Bachtell is the first to admit that the cannabis business is complicated. With all manner of different state regulations and federal legalization not yet realized, it’s not an easy industry to navigate. But it’s where Bachtell feels he belongs.

“I knew what the industry needed at that time, which was somebody to come in that had been through this kind of chaos before and knew how to normalize and professionalize an industry that people were concerned about.”

Investors are concerned too, he says, and fatigued by the lack of federal progress. Cannabis companies can’t trade on the New York Stock Exchange or Nasdaq while cannabis is federally illegal, and there is no shortage of OTC-traded companies jockeying for position.

But Bachtell believes Cresco Labs can become the most important company in cannabis. With a vibrant house of brands and an acquisition that more than doubles the company’s retail footprint, the mortgage lawyer turned cannabis CEO looks to have collected all the pieces to the puzzle.


This story was featured in Canadian Securities Exchange Magazine.

Learn more about Cresco Labs at www.crescolabs.com.

IM Cannabis: Early Mover Status Drives Growth in Multiple Legal Cannabis Markets

IM Cannabis (CSE:IMCC) Co-Founder and Chief Executive Officer Oren Shuster believes that entrepreneurs have to trust their “gut instincts” and follow the data to make good business decisions.

Earlier in his career, Shuster had co-founded with Rafael Gabay the Ewave software group, which was thriving with over 1,000 employees. Nevertheless, when the subject of medical cannabis came up during a meeting, Shuster’s instincts nudged him toward exploring its potential. 

“We started the Ewave technology group, and I quickly focused on healthcare technology. I’ve been one of the pioneers in developing web-based electronic medical records, radiology management and telemedicine solutions. But one day, a man talked to me about medical cannabis,” says Shuster. 

“As an entrepreneur, it got my attention, so I spoke with patients and doctors and collected data and feedback on medical cannabis. A light bulb went off in my head; I knew I had to do it – there’s something significant here for patients.”

With decades of experience in technology and medical ventures, Shuster then pivoted to co-found IM Cannabis, or IMC, in Israel.

In 2010, IMC sold its first batch of premium flower. The company is an outlier, and in a very good way, with operations in Israel, Canada and Germany, the world’s three largest federally legal markets.

Where most people see problems, entrepreneurs such as Shuster tend to see opportunity.

“A lot of cannabis companies went to Malta, as it was easy, but we went to Germany. A tough or challenging environment didn’t matter, as we have a strategic approach to Europe – not opportunistic,” says Shuster.

Germany legalized the medical use of cannabis in 2017. Shuster’s early push into the regulated German medical cannabis market has positioned IMC for high-octane growth as Europe’s largest economy presses ahead with plans to legalize cannabis for recreational use. German lawmakers are expected to introduce a draft bill on recreational cannabis legalization by the end of this year, according to media reports. 

“We’ve laid our foundation in Germany, currently one of the largest medical cannabis markets in the world, which is expected to rapidly expand as the German government enacts broad regulatory reform of cannabis use,” says Shuster. 

Undoubtedly, Germany legalizing cannabis for recreational use will be a seismic move for Europe. Tiny Luxembourg and Malta have given the go-ahead for people to grow and consume cannabis, but Germany is the continent’s biggest market.

Currently, IMC operates in Germany through its fully licensed EU-GMP subsidiary Adjupharm GmbH, which has built a logistics centre that allows it to repackage products. With the completion of the logistics centre, IMC has doubled its footprint in Germany to 8,000 square feet, upgraded its production facilities and increased its storage capacity to seven tons of cannabis. 

“IMC has a very clear strategy. What we’ve done is built the supply chain which starts with premium products in Canada going to our state-of-the-art EU-GMP facility in Germany. We are building it as the hub for the EU market,” explains Shuster. 

“We are in the best position to take a leadership position in the massive European market of 750 million people.”

In Germany, the IMC Hindu Kush strain has been a strong seller, helping make Adjupharm GmbH a top 10 cannabis company in the country. Adjupharm has initiated product licence applications to prepare for the launch of new high-quality THC products in the fourth quarter of this year and first quarter of 2023.

“We entered the Canadian market because we needed premium products for Germany and Israel. Our cannabis capacity in Canada is about 15,000 pounds (6,804 kilograms) annually, and we are not yet at full capacity. It’s all premium, indoor-grown Canadian cannabis,” notes Shuster.

“We are growing locally and selling in the Canadian market while supplying our other global markets. We’re also buying premium products from Canadian growers.”

IM Cannabis offers cannabis flower and strain-specific cannabis extracts under the IMC brand, plus dried flower, pre-rolls and pressed hash offerings under the WAGNERS and Highland Grow brands. IMC serves both medical and recreational consumers in Canada. 

IMC has launched a slew of new products in Canada in response to high demand for its WAGNERS and Highland Grow brands, which hold top-three spots in the premium and ultra-premium segments in Ontario, according to sales data from the Ontario Cannabis Store (OCS). 

The WAGNERS pre-roll catalog at the OCS has expanded with the launch of Tiki Rain, Blue Lime Pie and  TRPY ZLRP pre-rolls. Two new 3.5g dried flower stock keeping units (SKUs) – Tiki Rain and Purple Clementine – were launched in addition to an expansion of the concentrate portfolio, with the introduction of soft black hash and 3.5g soap bar hash. New product rollouts include Frost Bite, Leviathan and Space Jagger, according to the company.

“There are distinct advantages to being in different markets in diverse phases of maturity. The Canadian market is the most mature, fully legalized market with a variety of products. We’ve gained insights from being in an ultra-competitive market and can carry those insights to less mature markets,” says Shuster. 

IMC produces a full suite of distinct strains – Roma, Tel Aviv, London, Dairy Queen, Mango Mint, Lemongrass, Pecan Pie, Mimosa – and at least three different oils. The premium brands are aimed at high-end consumers and benefit IMC with premium pricing and higher margins.

“Most of our products are premium and occupy the highest category, as consumers are willing to pay more for quality and artisanal brands,” says Shuster.

While focusing on revenue growth, Shuster has also rigorously pursued cost and margin efficiencies at IMC. For its second quarter ended June 30, 2022, IMC reported C$23.8 million in revenue, a 114% increase from the same period in 2021.

IMC sold 3,210kg of dried flower during the quarter, at an average selling price of $5.72 per gram, compared to 1,842kg for the comparable quarter in 2021, at an average selling price of $3.92 per gram. 

IMC chalked up the jump in revenue to more medical and recreational cannabis sold at higher average selling prices per gram in Israel and Canada. The company’s gross profit, before fair value adjustments, was $5.6 million during the quarter, compared to $0.6 million in the second quarter of 2021.

“At the end of Q2, we had $5.8 million in the bank. We’ve accelerated along the path to profitability with increased revenue, operational streamlining and a focus on cost reduction,” says Shuster. 

“We are seeing growth and a revenue run rate of almost $100 million annually.

IMC has launched its Canadian WAGNERS brand in Israel and plans to bring new medical cannabis products to the country later this year. 

IMC’s de facto company, Focus Medical Herbs, closed its Sde Avraham cultivation farm in Israel, resulting in cash cost savings of $2.5 million per year. It has also finalized the sale of SublimeCulture and restructured its operations in Canada, yielding $4 million in annual cash savings.

A cautious risk-taker, Shuster has connected the dots of opportunity by building a diversified company with a global cannabis supply chain.

“I take calculated risks. I never put all my eggs in one basket, which is why IMC is geographically diversified with operations in Israel, Canada and Germany,” says Shuster.

“On legalization, we are primed to target new adult-use recreational cannabis markets in Germany and capture substantial market share across Europe.”

This story was featured in Canadian Securities Exchange Magazine.

Learn more about IM Cannabis at https://imcannabis.com.

Trulieve Cannabis: Staying True to Proven Growth Plans and Core Values Turns Trulieve Into a Cannabis Powerhouse

Trulieve Cannabis (CSE:TRUL) is one of the cannabis industry’s major success stories, with many of its biggest achievements occurring in the four years since it became a publicly traded company. The Trulieve team focused on innovating and leading Florida’s medical cannabis market at first and then expanded into new jurisdictions, the prudence of its strategy confirmed by strong profitability.

Importantly, this seed-to-sale, fully integrated multi-state operator is also making a mark by supporting the communities it calls home and championing cannabis policy reform.

As Trulieve Chief Executive Officer Kim Rivers explains, community and advocacy have been at the heart of the brand since the beginning.

In one example, Gadsden County, a majority-minority community in northern Florida where Trulieve built its first cultivation facility, has seen the company grow to become its leading employer, according to Rivers.

“We’ve had a material impact on the jobless rate there and pride ourselves on the difference we’ve made in that community,” Rivers says. “That story has been repeated in other communities that we’ve gone into, particularly on the cultivation and manufacturing side of the business.”

Since its launch in 2015, Trulieve has expanded quickly, now operating more than 4 million square feet of cultivation and processing capacity, more than 175 dispensaries and with operations in 11 states. The company is the largest medical cannabis operator in Florida, having recently celebrated the sixth anniversary of its first retail sale in the state, and is a top player in its other core markets of Pennsylvania and Arizona.

As it grows, the company has been able to keep its values of community and advocacy at the forefront by entering into new markets with specific characteristics. “Where we chose to make investments and how we chose to go into a community is thoughtful and purposeful,” Rivers explains. “It allows us opportunities to have a deeper connection with the communities, customers and patients that we serve.”

In addition to Trulieve’s internal community-focused initiatives, such as its supplier diversity program, the company works with a range of organizations, including the Epilepsy Foundation and veteran’s and children’s initiatives. Rivers also highlights the support of individuals qualifying for expungement of low-level cannabis offenses.  Among other benefits, expungement provides these individuals the opportunity to remove the conviction from their record, to participate in the industry and to vote to influence future cannabis policy.

A combination of customer focus and financial discipline has allowed Trulieve to thrive where other cannabis companies have not, Rivers notes.

“We made the decision early on to focus on branded products through branded retail, and we’re not shy or hesitant about growing our scale in both supply chain as well as our retail network,” she says. “That gives us the ability to build more durable relationships with the customer and have more control over the customer journey.”

This approach is clearly working, with the company reporting strong Q2 2022 results despite a challenging macroeconomic backdrop, including pressure on the company’s wholesale segment.

Trulieve reported a 49% year-over-year revenue increase in the quarter to US$320.3 million, including a 3% rise in retail revenue to $298.6 million. “We’re proud to see strong customer loyalty continue in the first half of the year,” says Rivers.

The company also posted a 17% EBITDA increase to $110 million and finished the quarter with $181.4 million in cash. 

The success of Trulieve’s approach is also evidenced by its expansion of operations into other markets, including Arizona, California, Massachusetts and Pennsylvania. Almost one-third of the company’s retail operations were located outside of Florida as of the end of the second quarter.

While Rivers notes that each new market has unique challenges due to differing regulations, Trulieve has found many aspects of its Florida business model to be transferrable, including operating and manufacturing procedures and market analysis.

According to Rivers, the company has been thoughtful in terms of how it can share resources across its broader platform and gain efficiencies where possible, citing the company’s nutrient program as an example.

Currently, the company is unable to transport cannabis products across state lines, but it can transport nutrients, and its nutrient blends are used across all of its sites in the US. “We also do a good bit of our research, development and innovation work in Florida because we have the ability to do that at scale,” she says.

Rivers also points to the company’s team as a key strategic advantage. “We have individuals who have operated within our Florida market and been a meaningful part of our scaling of operations from when we were initially three stores to now more than 100 stores in the state,” says Rivers. “Being able to take these lessons and apply learnings across different markets has been invaluable.”

For Trulieve, the year 2022 is about organic growth, as more states enhance their medical cannabis programs and pivot toward recreational use. Rivers says the company has focused on its branded products and branded retail while optimizing the portfolio of Arizona-based Harvest Health & Recreation, which the company acquired in a $2.1 billion all-stock deal in October 2021. 

As part of that effort, Trulieve divested non-core assets and operations, one recent example being the decision to discontinue wholesale operations in Nevada. 

“Sometimes it’s just as important what you don’t do as what you do,” Rivers says. “The goal is to enter 2023 as a stronger company positioned for the opportunities we see ahead of us.”

Despite recent remarks by political leaders in support of cannabis policy to cover state banking or criminal justice, Rivers notes that progress around cannabis reform on a federal level has been slow.

However, she remains hopeful that the encouraging discussions will morph into actual policy. “It’s very apparent that this is a popular issue due to the amount of conversation that it is getting before the midterm elections,” says Rivers.

One particularly important jurisdiction for Trulieve going forward is the southeast US. Rivers says the company has been “very bullish” on this region, citing recreational cannabis initiatives in Maryland as just one reason.

Another key area for growth is recreational cannabis opportunities in the company’s home state of Florida, which already has an 800,000-patient-strong medical cannabis market.

Trulieve backs the Smart and Safe Florida Act, a proposed constitutional amendment that would allow the recreational use of cannabis by people aged 21 or older in Florida. The company is hoping it will appear on Florida’s November 2024 ballot. Trulieve has contributed $5 million to help get the proposed amendment on the ballot.

“That will be a massive catalyst for our industry and certainly for our business, with 21 million residents in Florida and up to 130 million tourists visiting the state a year,” Rivers concludes. “We think our strategy will continue to serve us well in emerging markets as they develop but certainly also as the landscape on the federal side transforms.”

This story was featured in Canadian Securities Exchange Magazine.

Learn more about Trulieve Cannabis at www.trulieve.com

Beau Whitney on Data-driven Economic Models for Cannabis | The CSE Podcast Ep29-S2

The CSE’s Barrington Miller is joined by Beau Whitney, Founder of Whitney Economics, to discuss data-driven trends in cannabis globally, including US legalization, emerging markets, and environmental, social, and governance (ESG). The conversation also addresses how Whitney Economics uses data to help cannabis operators navigate the industry.

Here’s an overview of what Barrington and Beau discuss in this edition of The Exchange for Entrepreneurs Podcast:

00:00 – Introduction
02:00 – Global trends in the cannabis industry
03:28 – The cannabis industry in Canada and the US
07:05 – How do American cannabis companies differ from coast to coast? How is the industry shaped by state legislation?
11:33 – How do ESG (environmental and social governance) mandates tie into the valuation of multi-state operators?
14:40 – Is the current economic data contributing to the liberalization of cannabis policy in the US?
16:52 – What are the data points that have shifted over the last 7 years?
19:32 – Have there been any surprising individuals, organizations, and corporations that have reached out to collaborate?
22:59 – Within the business of data, who are Whitney Economics’ competitors and/or collaborators?
24:29 – Key findings from the business report that Whitney Economics published in 2020

About Beau Whitney

Whitney Economics was founded in October 2014 by Beau Whitney, in Portland Oregon. Mr. Whitney is currently the Chief Economist for the National Industrial Hemp Council (NIHC) and the National Cannabis Industry Association (NCIA). A member of the American Economic Association, the Oregon chapter president of the National Association of Business Economics and a participant in meetings of the Oregon council of economic advisors, he is widely regarded as one of the country’s leading cannabis economists. A registered member of the European Industrial Hemp Association, Mr. Whitney is also a member of multiple local regulatory advisory committees throughout the U.S. including the Oregon Liquor Control Commission (OLCC) RAC for both hemp and cannabis.

Learn more about Whitney Economics at https://whitneyeconomics.com/

Subscribe: Apple Podcasts / Spotify / Stitcher / Google Podcasts / iHeart / RSS

Alex Halperin on the State of the Cannabis Market in the US | The CSE Podcast Ep13-S2

CSE’s Barrington Miller is joined by Alex Halperin, Editor of WeedWeek, to discuss the cannabis industry in the United States, with a particular focus on the markets in California, New York, and the southern states. The conversation also dives into the dynamic of politics in US federal legalization, WeedWeek’s 2022 outlook, and the potential role of Big Pharma in the sector.

Here’s an overview of what Barrington and Alex discuss in this edition of the “Exchange for Entrepreneurs” podcast:

00:00 – Introduction and background
04:30 – Cannabis culture in California
07:30 – The challenge of running a cannabis business in California
11:00 – New York’s cannabis market
13:30 – Oklahoma’s cannabis market
17:30 – Texas’ cannabis market
19:10 – Cannabis legalization in Washington
22:20 – WeedWeek’s outlook on 2022
25:10 – What is Delta-8?
28:50 – Big Pharma’s involvement in the cannabis market

About WeedWeek
Business journalist Alex Halperin started writing the WeedWeek newsletter in 2015. It now has more than 8,000 subscribers including many of the most influential figures in the cannabis world. They appreciate WeedWeek’s incisive writing, aggressive reporting and that they are editorially independent. Advertisers have no influence on their editorial content. In 2020, they launched a major expansion and they now publish original reporting and analysis daily.

Learn more about WeedWeek at https://www.weedweek.com/

Subscribe: Apple Podcasts / Spotify / Stitcher / Google Podcasts / iHeart / RSS